Business Context and Reporting Period
This Form 8-K was filed by Alnylam Pharmaceuticals, Inc. on December 10, 2018, reporting an event that occurred on December 9, 2018. The filing details the resolution of ongoing legal disputes between Alnylam and Silence Therapeutics PLC and its subsidiary.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The financial impact is limited to the terms of a new licensing agreement and the cessation of litigation costs.
Material Changes and Agreement Terms
Alnylam and Silence Therapeutics entered into a Settlement and License Agreement resolving all global claims regarding patent infringement, invalidity, and breach of contract. Key terms include:
- Dispute Resolution: All claims and counterclaims were dismissed with prejudice. Each party bears its own attorney fees and costs.
- Liability: The agreement includes no admission of liability or wrongdoing by either party.
- Royalty Obligation: Silence is entitled to a tiered royalty of 0.33% to 1.0% on annual net sales of ONPATTRO (patisiran) in the European Union only, through 2023.
- License Grant: Silence granted Alnylam a fully paid-up, non-exclusive, global, irrevocable license to all relevant patents for current and future products (including ONPATTRO, vutrisiran, givosiran, lumasiran, inclisiran, fitusiran, cemdisiran, ALN-HBV02, ALN-AAT02, and investigational therapeutics). This license includes the right to sublicense to affiliates and collaborators with no additional milestones or royalties, except for the EU ONPATTRO royalty.
Outlook, Risks, and Management Commentary
The agreement eliminates the risk of ongoing litigation and regulatory proceedings between the two companies. By securing a fully paid-up global license for its pipeline, Alnylam removes potential patent barriers for its current and future products outside of the specific EU royalty obligation for ONPATTRO.
Investor Verification Checklist
- Verify the specific tiered royalty percentages (0.33% to 1.0%) and the sales thresholds triggering them for ONPATTRO in the EU.
- Confirm the exact list of patents covered under the "fully paid-up" license to ensure no critical IP is excluded.
- Assess the impact of the EU royalty obligation on the projected net sales margins for ONPATTRO through 2023.
- Review the dismissal of proceedings to ensure no residual regulatory risks remain in any jurisdiction.